Research institution
Gustave Roussy, Cancer Campus, Grand Paris Clinical Trials
Studies where Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 60Solid Tumor, Adult, Solid Tumor, Childhood
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.
- Conditions
- Solid Tumor, Adult, Solid Tumor, Childhood, Hematologic Cancer
- Trial name
- PIONEER (NCT05481502)
- Testing
- Tumor biopsy, Blood sample, Bone marrow sample
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Cancer
Implementing Precision Medicine in cOmmunity HospiTALs
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
- Trial name
- PRISM-POrTAL (NCT05283044)
- Testing
- biopsy liquid
- Where
- 21 sites in France, French Polynesia and 1 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Adult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 Gene
Reduce All Avoidable Cancer-promoting Exposures in Individuals at High Genetic Risk of Cancer Carrying a Constitutional Variant of the TP53 Gene
45% of cancer deaths are linked to modifiable factors (behavioral, metabolic). Li-Fraumeni syndrome (LFS), caused by germline TP53 mutations, leads to an extremely high, early-onset cancer risk (≈24× higher than general…
- Trial name
- LIFPREV (NCT07921537)
- Testing
- Single Group Assignment
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer Diagnosis, Moderate or Severe Score of Cancer-related Fatigue (CRF)
STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue
Decentralized, randomized hybrid type 2 (effectiveness/implementation) controlled trial comparing the effectiveness of three different digital aid modalities programs in reducing the perceived burden of CRF in cancer patients…
- Trial name
- STEPPING-STONe (NCT06505590)
- Testing
- Educational content, Educational material plus self-management program - self-administered version, Educational material plus self-management program - guided version with mental health professional
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
- Trial name
- OliGRAIL (NCT06840782)
- Testing
- Radical local treatment, SoC-based immunotherapy (+/- chemotherapy)
- Where
- 11 sites in France
- Volunteers
- 124 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Osteosarcoma, Pediatric Osteosarcoma
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
This clinical study is the initiative of the FOSTER (Fight OsteoSarcoma Through European Research) consortium and Gustave Roussy, which is the sponsor.
- Conditions
- Osteosarcoma, Pediatric Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Trial name
- FOSTER (NCT07871864)
- Testing
- Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles
- Where
- 77 sites in Denmark, Finland and 6 more
- Volunteers
- 530 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
The primary objective of this randomized phase II trial is to assess, independently in advanced/metastatic UPS and DDLPS, the antitumor activity of DT-7012 combined with doxorubicin as first-line systemic therapy.
- Trial name
- IMMUSARC-7012 (NCT07802652)
- Testing
- DT-7012, Doxorubicin
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreatic Adenocarcinoma Resectable, Non Metastatic
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
This is an open master platform trial, which includes multi neo-adjuvant treatment trials, multi-center, national. This platform trial evaluates the major pathological response rate (mPR) after surgery.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
- Trial name
- POWER (NCT07808567)
- Testing
- GnP, FOLFIRINOX
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumor, Leukemia
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
FMG2025 continues the previous efforts to propose treatment for patients based on the molecular characteristics of their tumor at treatment failure in cancer precision medicine trials within standard of care in France.
- Trial name
- MAPPYACTS2 (NCT05691608)
- Testing
- Solid tumor and CT DNA
- Where
- 29 sites in France
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris